VIVA Biotech Holdings
HKEX:1873
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/OCF
Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.
Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.
Valuation Scenarios
If EV/OCF returns to its 3-Year Average (7.2), the stock would be worth HK$1.78 (5% upside from current price).
| Scenario | EV/OCF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 6.9 | HK$1.7 |
0%
|
| 3-Year Average | 7.2 | HK$1.78 |
+5%
|
| 5-Year Average | 8.5 | HK$2.11 |
+24%
|
| Industry Average | 20.1 | HK$4.95 |
+191%
|
| Country Average | 20.8 | HK$5.14 |
+202%
|
Forward EV/OCF
Today’s price vs future operating cash flow
Peer Comparison
| Market Cap | EV/OCF | P/E | ||||
|---|---|---|---|---|---|---|
| CN |
V
|
VIVA Biotech Holdings
HKEX:1873
|
3.6B HKD | 6.9 | 14.3 | |
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
962.6B USD | 1 654.2 | 3 990.7 | |
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
173.9B USD | 25.4 | 25.4 | |
| US |
|
Danaher Corp
NYSE:DHR
|
127.8B USD | 21.7 | 34.7 | |
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
82.3T KRW | 36.2 | 46.1 | |
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
299.9B CNY | 15.5 | 15.7 | |
| CH |
|
Lonza Group AG
SIX:LONN
|
32.9B CHF | 32.1 | -122.9 | |
| US |
|
Agilent Technologies Inc
NYSE:A
|
32.7B USD | 24.6 | 25.3 | |
| US |
|
Waters Corp
NYSE:WAT
|
29.4B USD | 45.6 | 45.8 | |
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
27.8B USD | 14.9 | 20.5 | |
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
26B USD | 29.3 | 29.9 |
Market Distribution
| Min | 0 |
| 30th Percentile | 11.5 |
| Median | 20.8 |
| 70th Percentile | 39.2 |
| Max | 266 666.7 |
Other Multiples
VIVA Biotech Holdings
Glance View
Viva Biotech Holdings engages in preclinical research and development of innovative drugs. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2019-05-09. The firm is principally engaged in the provision of the structure-based drug discovery services to biotechnology and pharmaceutical customers worldwide for their pre-clinical stage innovative drug development. The Company’s core technologies include structure-based drug discovery (SBDD) platform, fragment-based drug discovery (FBDD) platform, affinity selection mass spectrometry (ASMS) screening platform and membrane protein targeted drug discovery platform. The firm operates its businesses mainly in the United States, China, Europe and other regions.
